Incyte (INCY) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue grew 9% year-over-year to $1.044 billion, driven by Jakafi and Opzelura, with strong U.S. and European demand.

• Reported a GAAP net loss of $444.6 million for Q2 2024, primarily due to one-time R&D charges from the Escient acquisition.

• Completed a $2 billion share repurchase, reducing outstanding shares by 14.8%, and finalized the Escient Pharmaceuticals acquisition.

• Strategic pipeline transformation with focus on high-potential programs, discontinuation of less competitive assets, and addition of first-in-class medicines from Escient.

• Gained exclusive global rights to tafasitamab (Monjuvi/Minjuvi) through a $25 million asset acquisition.

Financial highlights

• Jakafi net product revenue was $706 million (+3% year-over-year); Opzelura net product revenue reached $122 million (+52% year-over-year), with strong growth in both U.S. and Europe.

• Total royalty revenues were $137 million, up 8% year-over-year; Minjuvi/Monjuvi revenues rose 136% to $31 million.

• R&D expenses surged to $1.14 billion in Q2 2024, including $679–$691 million one-time Escient acquisition expense; excluding this, R&D was $692 million, up 13%.

• SG&A expenses were $306 million, up 8% year-over-year, mainly due to Escient-related costs.

• Cash, cash equivalents, and marketable securities totaled $1.4 billion as of June 30, 2024, down from $3.7 billion at year-end 2023.

Outlook and guidance

• Raised Jakafi full-year 2024 net revenue guidance to $2.71–$2.75 billion.

• Opzelura expected to continue growth, with expanded European reimbursement and seasonality impacting Q3.

• Updated R&D expense guidance (excluding Escient upfront) to $1.76–$1.80 billion.

• Maintained guidance for other hematology-oncology products and SG&A expenses.

• Management expects Jakafi to remain the primary revenue driver for the next several years.